Achilles Therapeutics plc (ACHL): Price and Financial Metrics
ACHL Price/Volume Stats
|Current price||$0.86||52-week high||$2.77|
|Prev. close||$0.88||52-week low||$0.75|
|Day high||$0.92||Avg. volume||192,519|
|50-day MA||$0.95||Dividend yield||N/A|
|200-day MA||$0.99||Market Cap||35.02M|
ACHL Stock Price Chart Interactive Chart >
ACHL Latest News Stream
|Loading, please wait...|
ACHL Latest Social Stream
View Full ACHL Social Stream
Latest ACHL News From Around the Web
Below are the latest news stories about ACHILLES THERAPEUTICS PLC that investors may wish to consider to help them evaluate ACHL as an investment opportunity.
- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice -LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“N
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.
ACHL Price Returns